

OTHER PUBLICATIONS

- Alexandridis, P. et al., "Temperature Effects of Structural Properties of Pluronic P104 and F108 PEO-PPO-PEO Block Copolymer Solutions," *Langmuir*, 11:1468-1476 (1995).
- Alkan-Onyuksel, H. et al., "A Mixed Micellar Formulation Suitable for the Parenteral Administration of Taxol," *Pharmaceutical Research*, 11(2):206-212 (1994).
- Alkan-Onyuksel, H. et al., "Development of Inherently Echogenic Liposomes as an Ultrasonic Contrast Agent," *Journal of Pharmaceutical Sciences*, 85(5):486-490 (May, 1996).
- Allen, T.M. et al., "Large Unilamellar Liposomes with Low Uptake into the Reticuloendothelial System," *Federation European Biochemical Societies*, 223(1):42-46 (Oct., 1987).
- Allen, T.M. et al., "Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo," *Biochimica et Biophysica Acta*, 1066:29-36 (1991).
- Almgren, M. et al., "Self-aggregation and phase behavior of poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) block copolymers in aqueous solution," *Colloid Polym Sci.*, 273:2-15 (1995).
- Artwohl, J.F. et al., "Initial Characterization of Hamsters with Spontaneous Hypertension," *FASEB J.*, 10:A628 (1996).
- Avidor, R. et al., "VIP-mRNA is increased in hypertensive rats," *Brain Research*, 503:304-307 (1989).
- Bangham, A.D. et al., "Diffusion of Univalent Ions across the Lamellae of Swollen Phospholipids," *J. Mol. Biol.*, 13:238-252 (1965).
- Beaumier, P.L. et al., "Effect of Liposome Dose on the Elimination of Small Unilamellar Sphingomyelin/Cholesterol Vesicles from the Circulation," *Research Communications in Chemical Pathology and Pharmacology*, 39(2):277-289 (Feb., 1983).
- Beaumier, P.L. et al., "Effects of Liposome Size on the Degradation of Bovine Brain Sphingomyelin/Cholesterol Liposomes in the Mouse Liver," *Biochimica et Biophysica Acta*, 731:23-30 (1983).
- Bedu-Addo, F.K. et al., "Interaction of Polyethyleneglycol-Phospholipid Conjugates with Cholesterol-Phosphatidylcholine Mixtures: Sterically Stabilized Liposome Formulations," *Pharmaceutical Research*, 13(5):718-724 (1996).
- Berisha, H. et al., "Vasoactive intestinal peptide prevents lung injury due to xanthine oxidase," *Am. J. Physiol.*, 259:L151-L155 (1990).
- Bodanszky, M. et al., "A Preferred Conformation in the Vasoactive Intestinal Peptide (VIP). Molecular Architecture of Gastrointestinal Hormones," *Bioorganic Chemistry*, 3:133-140 (1974).
- Bolin, D.R. et al., "Design and Development of a Vasoactive Intestinal Peptide Analog as a Novel Therapeutic for Bronchial Asthma," *Biopolymers, (Peptide Science)* 37:57-66 (1995).
- Carey, M.C. et al., "Micelle Formation by Bile Salts," *Arch Inter. Med.*, 130:506-527 (Oct., 1972).
- Chiba, K. et al., "Interaction Between Lipids and Bovine Brain Calmodulin: Lysophosphatidylcholine-Induced Conformation Change," *Life Science*, 47:953-960 (1990).
- Damrongchai, N. et al., "Calcium Responsive Two-Dimensional Molecular Assembling of Lipid-Conjugated Calmodulin," *Bioconjugate Chem.*, 6:264-268 (1995).
- DeGrado, W.F. et al., "Induction of Peptide Conformation at Apolar/Water Interfaces. 1. A Study with Model Peptides of Defined Hydrophobic Periodicity," *J. Am. Chem. Soc.*, 107:7684-7689 (1985).
- Demos, S.M. et al., "In Vitro Targeting of Antibody-Conjugated Echogenic Liposomes for Site-Specific Ultrasonic Image Enhancement," *Journal of Pharmaceutical Sciences*, 86(2):167-171 (Feb., 1997).
- Fournier, A. et al., "Synthesis, Conformational Studies and Biological Activities of VIP and Related Fragments," *Peptides* 5:169-177 (1984).
- Frase, L.L. et al., "Cardiovascular Effects of Vasoactive Intestinal Peptide in Healthy Subjects," *Am. J. Cardio.*, 60:1356-1361 (1987).
- Fry, D.C. et al., "Solution Structure of an Analogue of Vasoactive Intestinal Peptide As Determined by Two-Dimensional NMR and Circular Dichroism Spectroscopies and Constrained Molecular Dynamics," *Biochemistry*, 28:2399-2409 (1989).
- Gabizon, A. et al., "Liposome Formulations with Prolonged Circulation Time in Blood and Enhanced Uptake by Tumors," *Proc. Natl. Acad. Sci. (USA)*, 85:6949-6953 (Sep., 1988).
- Gao, X. et al., "Loop diuretics attenuate bradykinin-induced increase in clearance of macromolecules in the oral mucosa," *J. Appl. Physiol.*, 80(3):818-823 (1996).
- Gao, X. et al., "Vasoactive Intestinal Peptide Encapsulated in Liposomes: Effects on Systemic Arterial Blood Pressure," *Life Sciences*, 54(15): PL247-PL252 (1994).
- Gozes, I. et al., "VIP: Molecular Biology and Neurobiological Function," *Molecular Neurobiology*, 3:201-236 (1989).
- Gozes, I. et al., "Stearyl-Norleucine-Vasoactive Intestinal Peptide (VIP): A Novel VIP Analog for Noninvasive Impotence Treatment," *Endocrinology*, 134(5):2121-2125 (1994).
- Gozes, I. et al., "Superactive Lipophilic Peptides Discriminate Multiple Vasoactive Intestinal Peptide Receptors," *J. Pharmacology Experimental Therapeutics*, 273(1):161-167 (1995).
- Gregoriadis, G. et al., "Fate of Protein-Containing Liposomes Injected into Rats: An Approach to the Treatment of Storage Diseases," *Eur. J. Biochem.* 24:485-491 (1972).
- Gregoriadis, G. et al., "Liposomes in Drug Delivery: Clinical, Diagnostic and Ophthalmic Potential," *Drugs*, 45(1):15-28 (1993).
- Haghjoo, K. et al., "Solution Structure of Vasoactive Intestinal Polypeptide (11-28)-NH₂, a Fragment with Analgesic Properties," *Peptide Research*, 9(6):327-331 (1996).
- Hamed, M.M. et al., "Behavior of Amphipathic Helices on Analysis via Matrix Methods, with Application to Glucagon, Secretin, and Vasoactive Intestinal Peptide," *Biopolymers*, 22:1003-1021 (1983).
- Hirata, Y. et al., "Functional Receptors For Vasoactive Intestinal Peptide In Cultured Vascular Smooth Muscle Cells From Rat Aorta," *Biochemical Biophysical Research Communications*, 132(3):1079-1087 (Nov., 1985).
- Hjelm, R.P. Jr. et al., "Organization of Phosphatidylcholine and Bile Salt in Rodlike Mixed Micelles," *J. Phys. Chem.*, 96(21):8653-8661 (1992).
- Hökfelt, T., "Neuropeptide in Perspective: The Last Ten Years," *Neuron*, 7:867-879 (1991).